EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation

Ellen Werner iD, Maria C B van Hooff, Gemma H X Weijsters, Maria A van de Vrie, Rozanne C de Veer iD, Ulrich Beuers, Joost P H Drenth iD, Frans J C Cuperus, Remco van Dijk, Bart J Veldt, Michael Klemt-Kropp, Suzanne van Meer und 25 weitere

Alimentary Pharmacology & Therapeutics · 2026-07 · 64 (2) · 186-195

DOI: 10.1111/apt.70669 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 14.04.2026. Verfasst von Ellen Werner und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, Liver Cirrhosis, Biliary, Cholagogues and Choleretics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Zambon Nederland B.V.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Optimal care delivery for primary biliary cholangitis (PBC) has become challenging due to new therapies and more individualized biochemical treatment goals.

Aim

To evaluate uptake of ursodeoxycholic acid (UDCA) and second‐line therapy (SLT) in a nationwide PBC cohort and identify factors associated with suboptimal therapeutical management.

Methods

The Dutch PBC Cohort Study is a retrospective study including every identifiable patient with PBC in the Netherlands from 1990 onwards. Use of UDCA and SLT was assessed among patients in clinical follow‐up on 1 January 2019. Biochemical response was defined as alkaline phosphatase (ALP) and aspartate aminotransferase (AST) ≤ 1.5 × ULN and total bilirubin (TB) ≤ ULN. SLT included off‐label fibrates, budesonide and/or obeticholic acid (not reimbursed).

Results

In total, 2638 patients with PBC were included; median age was 64.0 (IQR 55.0–72.0) years, 2361 (89.5%) were female and 2143 (81.2%) were treated in a non‐academic center. Overall, 2532 (96.0%) patients used UDCA. The recommended UDCA dose of ≥ 13 mg/kg/day was used by 1363/2205 (61.8%). Age (aOR 1.01, 95% CI 1.00–1.02, p = 0.02), body weight (aOR 1.04, 95% CI 1.03–1.05, p < 0.01) and biochemical response (aOR 1.35, 95% CI 1.09–1.67, p = 0.01) were associated with UDCA dosage < 13 mg/kg/day. Among patients with an incomplete response, 101/638 (15.8%) were prescribed SLT. Younger age, female sex, treatment in an academic centre and higher levels of ALP and AST were positively associated with use of SLT.

Conclusions

During recent years, UDCA was insufficiently dosed in Dutch patients with PBC. The results indicate that first‐line treatment can be optimized, especially in those with a biochemical response and higher body weight.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ursodeoxycholic AcidLiver Cirrhosis, BiliaryCholagogues and CholereticsHumansFemaleNetherlandsRetrospective StudiesMiddle AgedAgedMaleChenodeoxycholic AcidBudesonideAlkaline PhosphataseFibric Acids

Stichwörter der Autor:innen

primary biliary cholangitissecond‐line therapyursodeoxycholic acid

Substanzen

Ursodeoxycholic AcidCholagogues and CholereticsChenodeoxycholic AcidBudesonideobeticholic acidAlkaline PhosphataseFibric Acids

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
  • Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Gastroenterology and Hepatology Reinier de Graaf Gasthuis, Delft, the Netherlands.
  • Department of Gastroenterology and Hepatology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands.

ORCID-Profile: Ellen Werner, Rozanne C de Veer, Joost P H Drenth, Robert C Verdonk, Matthijs Kramer, Nicole S Erler, Adriaan J van der Meer

Förderung

  • Zambon Nederland B.V

Zitieren

APA

Werner, E., van Hooff, M. C. B., Weijsters, G. H. X., van de Vrie, M. A., de Veer, R. C., Beuers, U., Drenth, J. P. H., Cuperus, F. J. C., van Dijk, R., Veldt, B. J., Klemt-Kropp, M., van Meer, S., Verdonk, R. C., Flink, H. J., Vrolijk, J. M., Kramer, M., Ponsioen, C. Y., Boonstra, K., Boersma, F., …, & Dutch PBC Study Group (2026). A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation. Alimentary Pharmacology & Therapeutics, 64(2), 186-195. https://doi.org/10.1111/apt.70669

Vancouver

Werner E, van Hooff MCB, Weijsters GHX, van de Vrie MA, de Veer RC, Beuers U, et al. A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation. Alimentary Pharmacology & Therapeutics. 2026;64(2):186-195. doi:10.1111/apt.70669

BibTeX
@article{Werner2026,
  author = {Werner, Ellen and van Hooff, Maria C B and Weijsters, Gemma H X and van de Vrie, Maria A and de Veer, Rozanne C and Beuers, Ulrich and Drenth, Joost P H and Cuperus, Frans J C and van Dijk, Remco and Veldt, Bart J and Klemt-Kropp, Michael and van Meer, Suzanne and Verdonk, Robert C and Flink, Hajo J and Vrolijk, Jan Maarten and Kramer, Matthijs and Ponsioen, Cyriel Y and Boonstra, Kirsten and Boersma, Femke and de Jonge, Hendrik J M and Wolfhagen, Frank H J and Baak, L C and Onderwater, Susanne L and van Bergeijk, Jeroen D and van Putten, Paul G and de Bruin, Gijs J and Adang, Rob P R and Aparicio-Pages, Maria N and de Boer, Wink and Ter Borg, Frank and van Soest, Hanneke and de Vries, Elsemieke S and Erler, Nicole S and Hansen, Bettina E and Janssen, Harry L A and van der Meer, Adriaan J and Dutch PBC Study Group, Dutch PBC Study Group},
  title = {A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {2},
  pages = {186--195},
  doi = {10.1111/apt.70669}
}
Kostenlos starten →